AnaptysBio Is Maintained at Buy by Guggenheim
Leerink Partners Maintains AnaptysBio(ANAB.US) With Buy Rating
"Buy" Rating for AnaptysBio Driven by Promising Preclinical Data on Rosnilimab's Ulcerative Colitis Treatment Potential
Piper Sandler Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $80
Analysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (EWTX) and AnaptysBio (ANAB)
Piper Sandler Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $80
AnaptysBio Analyst Ratings
Wedbush Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $42
J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating
J.P. Morgan Reaffirms Their Buy Rating on AnaptysBio (ANAB)
BTIG Initiates AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $55
AnaptysBio Price Target Raised to $30.00/Share From $20.00 by Truist Securities
Truist Financial Sticks to Its Hold Rating for AnaptysBio (ANAB)
AnaptysBio Analyst Ratings
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $55 Price Target
H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $55
AnaptysBio: Strong Buy Rating on Robust Equity Raise and Promising Clinical Pipeline
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Charles River Labs (CRL) and Akero Therapeutics (AKRO)
JP Morgan Maintains Overweight on AnaptysBio, Raises Price Target to $75
Wedbush Maintains AnaptysBio(ANAB.US) With Buy Rating, Raises Target Price to $42